Daily IP News: 18/10/2010


1) Biocon and Pfizer Enter Into Global Commercialization Agreement (Pfizer Press Release).

Pfizer will have exclusive license to commercialize biocon’s biosimilar versions of Recombinant Human Insulin, Glargine , Aspart and Lispro (all are long/fast acting insulin analogs).

… Under the terms of the agreement, Pfizer will make upfront payments totaling $200 million.  Biocon is also eligible to receive additional development and regulatory milestone payments of up to $150 million and will receive additional payments linked to Pfizer’s sales of its four Insulin biosimilar products across global markets….

2) Venus Remedies drug wins Australia, Ukraine patents (ET report).

Note: Indian patent office also allowed this patent 2510/DEL/2004 (Decision Copy) granted as 235775. WO2006064516 (AU2005315140B2; a200707601)

3) Transfer of Manufacturing and Marketing Approval and Distribution Rights for the Anti-Allergic Drug “Intal®” (Sodium cromoglycate) (Press release)

Advertisements

About Guna

Interested to learn things around me
This entry was posted in Daily interesting IP news. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s